MT200605入选MDS 2026：全球首创TrkB激动剂亮相运动障碍国际学术年会

点击蓝字 关注我们

      2026年10月4日至8日，国际帕金森与运动障碍学会（MDS）2026年国际大会将于韩国首尔举行，麦科奥特自主研发的全球首创MT200605在亨廷顿病研究成果已正式入选本届会议，并将以壁报（Poster）形式面向全球学界发布。

     MDS国际大会由国际帕金森与运动障碍学会主办，涵盖帕金森病、亨廷顿病、肌张力障碍、共济失调等全部运动障碍疾病谱系，是全球该领域学术门槛最高的年度集会。

注：图片来源于大会官方海报，侵删

      亨廷顿病被称为史上最残酷的遗传病，是一种常染色体显性遗传的神经退行性疾病，由HTT基因CAG重复扩增导致突变亨廷顿蛋白（mHTT）异常聚集，引发集运动障碍、认知衰退及精神异常症状于一体的“三重打击”疾病。患者发病后中位生存期约15-20年，美国约有4.1万名有症状患者，全球患者总数约40万人。目前尚无获批的疾病修饰疗法，现有治疗仅限症状管理。

The International Congress of Parkinson’s Disease and Movement Disorders® 2026, organized by the International Parkinson and Movement Disorder Society (MDS), will be held in Seoul, Korea. MT200605, a first-in-class candidate independently developed by Micot, has been officially accepted for presentation at this year’s Congress for its research findings in Huntington’s disease and will be presented to the global academic community as a poster presentation.

Organized by the International Parkinson and Movement Disorder Society, the MDS International Congress covers the full spectrum of movement disorders, including Parkinson’s disease, Huntington’s disease, dystonia, and ataxia. It is one of the world’s leading annual academic congresses in the field.

Note: Images are from the official poster of the conference. For infringement, please contact us for removal.

Huntington’s disease is often regarded as one of the most devastating inherited disorders. It is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the HTT gene, leading to abnormal aggregation of mutant huntingtin protein (mHTT). The disease imposes a “triple burden” of motor dysfunction, cognitive decline, and psychiatric manifestations. 

After onset, median survival is approximately 15–20 years. In the United States, approximately 41,000 people have symptomatic Huntington’s disease, while the global patient population is estimated at around 400,000. To date, no disease-modifying therapy has been approved, and existing treatments remain limited to symptom management.